Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (842)	10/17/1998 12:57:00 PM
From: StockDoc	Read Replies (1) \| Respond to of 887

I am delighted to see your unbroken optimism. Was the ODAC for Nov. 16th in the news? I don't get this "invitation" for a new NDA thing. In fact, I doubt that FDA formally "invited" an NDA. I thought everything went according to original plans: 3 independent and subsequent submissions for 3 indications. The first submission for carcinomatous meningitis, unfortunately, failed. Two more to go: lymphomatous meningitis (apparently next month or so)and leukemia meningitis. FDA probably recommended DEPO to submit their data on the lymphoma arm to further assess the merits of Depocyt. This could get interpreted as an "invitation". Just a note: the drug is not intended for and haven't been tested in H&N cancer. Good luck.